Trial Profile
Pilot Study of Obinutuzumab in Combination With GDP Chemotherapy for the Treatment of Relapsed or Refractory CD20+ Aggressive Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Dexamethasone (Primary) ; Gemcitabine (Primary) ; Obinutuzumab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 11 Apr 2021 Status changed from active, no longer recruiting to completed.
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 25 Sep 2018 Status changed from recruiting to active, no longer recruiting.